OpGen (NASDAQ:OPGN) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGNGet Free Report) in a research report issued to clients and investors on Monday. The firm set a “sell” rating on the medical research company’s stock.

OpGen Price Performance

Shares of OPGN stock opened at $1.16 on Monday. OpGen has a one year low of $0.53 and a one year high of $9.90. The company’s 50-day moving average is $1.18 and its 200 day moving average is $1.82.

About OpGen

(Get Free Report)

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.

Featured Stories

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.